<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635788</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5359</org_study_id>
    <secondary_id>30104</secondary_id>
    <nct_id>NCT03635788</nct_id>
  </id_info>
  <brief_title>The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE</brief_title>
  <official_title>A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy, safety, and durability of two different&#xD;
      strategies to treat participants with a history of sub-optimal adherence and control of their&#xD;
      HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care&#xD;
      (SOC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the efficacy, safety, and durability of two different strategies to&#xD;
      treat participants with a history of sub-optimal adherence and control of their HIV&#xD;
      infection: long-acting (LA) antiretroviral therapy (ART) with rilpivirine (RPV) LA and&#xD;
      cabotegravir (CAB) LA versus all-oral standard of care (SOC).&#xD;
&#xD;
      The study includes four steps. In Step 1, participants will receive a SOC oral induction&#xD;
      regimen consisting of an ART regimen that involves at least 3 drugs for 24 weeks.&#xD;
      Participants who achieve milestones will receive conditional economic incentives at Weeks 2,&#xD;
      4, 8, 12, 16, and 20.&#xD;
&#xD;
      In Step 2, eligible participants will be randomized to receive either oral RPV + oral CAB for&#xD;
      4 weeks followed by RPV-LA + CAB-LA every 4 weeks for 48 weeks or to continue on SOC for 52&#xD;
      weeks.&#xD;
&#xD;
      At the completion of Step 2, eligible participants randomized to SOC will have the option to&#xD;
      register to Step 3 and receive LA ART, which includes oral RPV + oral CAB for 4 weeks&#xD;
      followed by RPV-LA + CAB-LA every 4 weeks for 48 weeks. Participants already receiving RPV-LA&#xD;
      + CAB-LA in Step 2 will continue on this regimen in Step 3 for 52 weeks.&#xD;
&#xD;
      Eligible participants will enter Step 4 and be followed for 52 weeks on locally sourced oral&#xD;
      ART.&#xD;
&#xD;
      Participants will be followed for up to a total of 180 weeks. Study visits, which will occur&#xD;
      throughout the study, may include physical examinations; blood, urine, and hair collection;&#xD;
      liver function tests; questionnaires; and an electrocardiogram (ECG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to regimen failure in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Time will be measured from Step 2 randomization to the first of the following two events: virologic failure or permanent discontinuation of randomized study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Virologic failure is defined as confirmed HIV-1 RNA greater than 200 copies/mL after Step 2 randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the treatment-related failure in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Time will be measured from the Step 2 randomization to the first of the following events: virologic failure or treatment discontinuation due to adverse event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with virologic success</measure>
    <time_frame>Measured through Step 2, Week 48</time_frame>
    <description>Virologic success will be defined by the US Food and Drug Administration (FDA) Snapshot algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with plasma HIV-1 RNA level less than 50 copies/mL</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Number of participants with plasma HIV-1 RNA level less than 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>AEs will be graded based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation of randomized treatment in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Time will be measured from Step 2 randomization to the permanent discontinuation of randomized study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary score of HIV Treatment Satisfaction Questionnaire (HIVTSQ)</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Summary score of HIV Treatment Satisfaction Questionnaire (HIVTSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pill count in Step 1</measure>
    <time_frame>Measured through Step 1, Week 24</time_frame>
    <description>Pill count in Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pill count for participants who randomized to SOC arm in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Pill count for participants who randomized to SOC arm in Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of missed or delayed injections for participants who received LA ART in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Frequency of missed or delayed injections for participants who received LA ART in Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary scores of HIV Treatment Adherence Self-Efficacy Scale</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Summary scores of HIV Treatment Adherence Self-Efficacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of new drug-resistance mutations in participants with virologic failure in Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Summarized and tabulated by randomized treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Injection Site Reactions (ISR) during Step 2</measure>
    <time_frame>Measured through Step 2, Week 52</time_frame>
    <description>Frequency of Injection Site Reactions (ISR) during Step 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 52 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SOC) Oral ART</intervention_name>
    <description>SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral RPV</intervention_name>
    <description>RPV 25 mg tablets</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Rilpivirine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral CAB</intervention_name>
    <description>CAB 30 mg tablets</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Cabotegravir</other_name>
    <other_name>GSK1265744</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPV-LA Loading Dose</intervention_name>
    <description>900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Rilpivirine Long-Acting Injectable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAB-LA Loading Dose</intervention_name>
    <description>600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Cabotegravir Long-Acting Injectable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPV-LA Maintenance Dose</intervention_name>
    <description>600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Rilpivirine Long-Acting Injectable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAB-LA Maintenance Dose</intervention_name>
    <description>400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle</description>
    <arm_group_label>Arm A: LA ART</arm_group_label>
    <arm_group_label>Arm B: SOC Oral ART</arm_group_label>
    <other_name>Cabotegravir Long-Acting Injectable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Step 1 Inclusion Criteria&#xD;
&#xD;
          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or&#xD;
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and&#xD;
             confirmed by a licensed Western blot or a second antibody test by a method other than&#xD;
             the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.&#xD;
&#xD;
               -  NOTE: The term &quot;licensed&quot; refers to a FDA-approved kit, which is required for all&#xD;
                  IND studies.&#xD;
&#xD;
               -  WHO (World Health Organization) and CDC (Centers for Disease Control and&#xD;
                  Prevention) guidelines mandate that confirmation of the initial test result must&#xD;
                  use a test that is different from the one used for the initial assessment. A&#xD;
                  reactive initial rapid test should be confirmed by either another type of rapid&#xD;
                  assay or an E/CIA that is based on a different antigen preparation and/or&#xD;
                  different test principle (e.g., indirect versus competitive), or a Western blot&#xD;
                  or a plasma HIV-1 RNA viral load.&#xD;
&#xD;
          -  HIV-1 Plasma viral load (VL) greater than 200 copies/mL within 60 days prior to study&#xD;
             entry by any US laboratory that has a Clinical Laboratory Improvement Amendments&#xD;
             (CLIA) certification or its equivalent.&#xD;
&#xD;
          -  Evidence of non-adherence to ART according to at least one of the following criteria:&#xD;
&#xD;
               -  Poor virologic response within 18 months prior to study entry (defined as less&#xD;
                  than 1 log10 decrease in HIV-1 RNA or HIV-1 RNA greater than 200 copies/mL at two&#xD;
                  time points at least 4 weeks apart) in individuals who have been prescribed ART&#xD;
                  for at least 6 consecutive months.&#xD;
&#xD;
               -  Lost to clinical follow-up within 18 months prior to study entry with ART&#xD;
                  non-adherence for greater than or equal to 6 consecutive months.&#xD;
&#xD;
               -  NOTE: Lost to clinical follow-up is defined as either no contact with provider or&#xD;
                  missed greater than or equal to 2 appointments in a 6-month period. ART&#xD;
                  non-adherence is defined as a lapse in ART greater than or equal to 7 days&#xD;
                  (consecutive or non-consecutive), in the 6-month period where they were lost to&#xD;
                  clinical follow-up per participant report.&#xD;
&#xD;
          -  No evidence of any clinically relevant RPV or INSTI resistance-associated mutations&#xD;
             (see Manual of Procedures [MOPS] for list of exclusionary mutations) through&#xD;
             commercially available genotypic (or phenotypic, if available) analyses from any&#xD;
             laboratory that has a CLIA certification or its equivalent within 60 days of study&#xD;
             entry (see protocol for more information), nor history of such mutations on review of&#xD;
             prior resistance tests by the site investigator. Genotypic analysis using proviral&#xD;
             (i.e., archived) DNA is not allowed.&#xD;
&#xD;
          -  Ability of site clinician, in conjunction with participant, to construct an oral&#xD;
             induction antiretroviral (ARV) regimen that must include at least three ARVs of which&#xD;
             at least two must be predicted to be fully active. The regimen must, include PI/cobi&#xD;
             and/or an INSTI based on screening and/or historic resistance testing.&#xD;
&#xD;
          -  Laboratory values obtained within 60 days prior to study entry by any laboratory that&#xD;
             has a CLIA certification or its equivalent:&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 600/mm^3&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Creatinine Clearance (CrCl) greater than or equal to 50 mL/min estimated by&#xD;
                  Cockcroft-Gault&#xD;
&#xD;
               -  NOTE: A calculator for estimating the CrCl can be found at&#xD;
                  www.fstrf.org/ACTG/ccc.html.&#xD;
&#xD;
          -  For women of reproductive potential, negative serum or urine pregnancy test with a&#xD;
             sensitivity of less than or equal to 25 mIU/mL at screening. This will be repeated&#xD;
             again at study entry.&#xD;
&#xD;
               -  NOTE: Female participants are considered to be NOT of reproductive potential if:&#xD;
                  1) they have had amenorrhea for at least 12 consecutive months prior to study&#xD;
                  entry ((i.e., who have had no menses within 12 months prior to study entry), and&#xD;
                  have a documented follicle-stimulating hormone (FSH) greater than 40 IU/mL; OR 2)&#xD;
                  an FSH level is not available, but they have had 24 consecutive months of&#xD;
                  amenorrhea (in the absence of medications known to induce amenorrhea); OR 3) they&#xD;
                  report having undergone surgical sterilization (e.g., hysterectomy, or bilateral&#xD;
                  oophorectomy, or bilateral tubal ligation/hysteroscopic tubal occlusion).&#xD;
&#xD;
          -  Contraception requirements&#xD;
&#xD;
               -  Female Participants of Reproductive Potential: Female participants of&#xD;
                  reproductive potential, who are participating in sexual activity that could lead&#xD;
                  to pregnancy, must agree to use at least one of the listed highly effective&#xD;
                  methods for contraception from 30 days prior to the first dose of study&#xD;
                  medication, while receiving the study drugs, and for 30 days after stopping oral&#xD;
                  medications, or the duration specified in the product label if receiving study&#xD;
                  drugs not supplied by the study, or 52 weeks after stopping RPV-LA or CAB-LA.&#xD;
                  Acceptable methods of contraception include:&#xD;
&#xD;
                    -  Contraceptive subdermal implant&#xD;
&#xD;
                    -  Intrauterine device or intrauterine system&#xD;
&#xD;
                    -  Combined estrogen and progestogen oral contraceptive&#xD;
&#xD;
                    -  Injectable progestogen&#xD;
&#xD;
                    -  Contraceptive vaginal ring&#xD;
&#xD;
                    -  Percutaneous contraceptive patches&#xD;
&#xD;
               -  Female Participants Who Are Not of Reproductive Potential: Women who are not of&#xD;
                  reproductive potential are eligible to start study drugs without requiring the&#xD;
                  use of contraceptives. Any statement of self-reported sterility or that of her&#xD;
                  partner's must be entered in the source documents.&#xD;
&#xD;
               -  NOTE A: Acceptable documentation of lack of reproductive potential is the woman's&#xD;
                  self-reported history of surgical sterilization, menopause, or male partner's&#xD;
                  azoospermia.&#xD;
&#xD;
               -  NOTE B: ALL participants in the study should be counseled on safer sexual&#xD;
                  practices including the use and benefit/risk of effective barrier methods (e.g.,&#xD;
                  male condom) and on the risk of HIV transmission to an uninfected partner.&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Ability and willingness of participant or legal guardian/representative to provide&#xD;
             written informed consent.&#xD;
&#xD;
        Step 1 Exclusion Criteria&#xD;
&#xD;
          -  Currently pregnant, planning to become pregnant during the study period, or currently&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Participants determined by the Site Investigator to have a high risk of seizures,&#xD;
             including participants with an unstable or poorly controlled seizure disorder.&#xD;
&#xD;
               -  NOTE: A participant with a prior history of seizure may be considered for&#xD;
                  enrollment if the Investigator believes the risk of seizure recurrence is low.&#xD;
                  All cases of prior seizure history should be discussed with the A5359 protocol&#xD;
                  leadership team (actg.leada5359@fstrf.org) prior to enrollment.&#xD;
&#xD;
          -  Advanced liver disease (as defined by any of the following: presence of ascites,&#xD;
             encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or&#xD;
             persistent jaundice), known biliary abnormalities (with the exception of Gilbert's&#xD;
             syndrome or asymptomatic gallstones) OR history of liver cirrhosis.&#xD;
&#xD;
          -  Chronic Hepatitis C (HCV) with planned or anticipated use of anti-HCV therapy prior to&#xD;
             the completion of Step 2.&#xD;
&#xD;
          -  History of or current active hepatitis B (HBV) infection defined as positive HBV&#xD;
             surface antigen test or any detectable HBV DNA in participants with isolated HBcAb and&#xD;
             HBV DNA as follows:&#xD;
&#xD;
               -  Participants positive for HBsAg are excluded&#xD;
&#xD;
               -  Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg&#xD;
                  status) and any detectable HBV DNA are excluded&#xD;
&#xD;
               -  NOTE: Participants positive for anti-HBc (negative HBsAg status) and positive for&#xD;
                  anti-HBs (past and/or current evidence) are immune to HBV and are not excluded.&#xD;
&#xD;
          -  Current or anticipated need for chronic anti-coagulation therapy.&#xD;
&#xD;
          -  Unwilling to receive injections, or unable to receive gluteal injections.&#xD;
&#xD;
          -  Tattoo or other condition over gluteus region, which may interfere with interpretation&#xD;
             of injection site reaction.&#xD;
&#xD;
          -  Previous use of CAB.&#xD;
&#xD;
          -  Acute or serious illness requiring systemic treatment and/or hospitalization within 7&#xD;
             days prior to entry.&#xD;
&#xD;
          -  QTc greater than 450 ms using either Bazett or Fridericia method within 60 days prior&#xD;
             to study entry: Whichever method is used at screening must be used throughout study&#xD;
             period.&#xD;
&#xD;
          -  Any serious medical or psychiatric condition, which may render the participant unable&#xD;
             to receive study medication in the opinion of the site investigator.&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or&#xD;
             their formulation.&#xD;
&#xD;
          -  Requirement for any medication that is prohibited with a study medication (refer to&#xD;
             protocol specific web page [PSWP]).&#xD;
&#xD;
        Step 2 Inclusion Criteria&#xD;
&#xD;
          -  HIV-1 RNA less than 50 copies/mL at Step 1, week 20, or HIV-1 RNA of 50-399 copies/mL&#xD;
             at Step 1, week 20, followed by HIV-1 RNA less than 50 copies/mL by Step 1, week 24.&#xD;
&#xD;
        Step 2 Exclusion Criteria&#xD;
&#xD;
          -  Permanent discontinuation of study treatment for any reason during Step 1.&#xD;
&#xD;
          -  Participants who never started study treatment in Step 1 (see protocol for more&#xD;
             information)&#xD;
&#xD;
        Step 3 Inclusion Criteria&#xD;
&#xD;
          -  Willingness to continue for those in Arm A or begin to receive LA ART for those in Arm&#xD;
             B.&#xD;
&#xD;
          -  Arm B participants: HIV-1 RNA less than 50 copies/mL at Step 2, week 48, or HIV-1 RNA&#xD;
             of 50-399 copies/mL at Step 2, week 48, followed by HIV-1 RNA less than 50 copies/mL&#xD;
             by Step 2, week 52.&#xD;
&#xD;
        Step 3 Exclusion Criteria&#xD;
&#xD;
          -  Permanent discontinuation of study treatment for any reason during Step 2.&#xD;
&#xD;
        Step 4 Inclusion Criteria&#xD;
&#xD;
          -  Any participant who has received at least one dose of CAB-LA or RPV-LA AND does not&#xD;
             have access to commercially available LA ART,&#xD;
&#xD;
          -  OR does not wish to continue LA ART.&#xD;
&#xD;
        Step 4 Exclusion Criteria&#xD;
&#xD;
          -  There are no exclusion criteria for Step 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Castillo-Mancilla, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado Hospital CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aadia Rana, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Alabama CTU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Heard, M.P.H.</last_name>
      <phone>205-996-4405</phone>
      <email>fhoward@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis M. Mendez</last_name>
      <phone>323-343-8283</phone>
      <email>lmendez@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleen Khodabakhshian</last_name>
      <phone>310-557-9027</phone>
      <email>akhodabakhshian@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Dwyer</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>353</phone_ext>
      <email>Jay.Dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@labiomed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo, M.S.P.H.</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saniyyah Mahmoudi, A.R.N.P.</last_name>
      <phone>904-244-5331</phone>
      <email>saniyyah.mahmoudi@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick, M.S.N.</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins, M.P.H.</last_name>
      <phone>312-695-5012</phone>
      <email>Baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mall, R.N.</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Becker, P.A.-C</last_name>
      <phone>410-614-4036</phone>
      <email>rbecke22@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N.</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl E. Keenan, R.N.</last_name>
      <phone>617-732-5635</phone>
      <email>CKeenan@BWH.Harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K. Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rondalya DeShields, R.N., B.S.N.</last_name>
      <phone>973-972-3729</phone>
      <email>deshierd@njms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Burey, R.N., M.S.N., P.N.P.</last_name>
      <phone>718-918-4783</phone>
      <email>marlene.burey@nychhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Stroberg, R.N., B.S.N.</last_name>
      <phone>212-746-7198</phone>
      <email>tstrober@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Palmer, P.A. -C</last_name>
      <phone>212-342-2958</phone>
      <email>sp500@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, M.S.N., FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Infanzon</last_name>
      <phone>631-444-8832</phone>
      <email>Erin.Infanzon@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greensboro CRS</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Epperson, R.N., B.S.N., CRC</last_name>
      <phone>336-832-3262</phone>
      <email>kim.epperson@conehealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs, R.N., B.S.N.</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Baum, R.N.</last_name>
      <phone>216-844-2546</phone>
      <email>jb@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson, B.S.N., R.N.</last_name>
      <phone>614-293-5856</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics, CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen B. Donaghy, C.R.N.P.</last_name>
      <phone>215-349-8092</phone>
      <email>eileen.donaghy2@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn R. Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital Clinical Research Site (TMH CRS) CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Poethke, R.N.</last_name>
      <phone>401-793-4971</phone>
      <email>ppoethke@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly O. Woodward, M.S.N., R.N.</last_name>
      <phone>615-936-8516</phone>
      <email>beverly.o.woodward@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L. Martinez</last_name>
      <phone>713-500-6718</phone>
      <email>Maria.L.Martinez@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jonsson, EMBA</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia I. Davila Nieves, M.Sc.</last_name>
      <phone>787-767-9192</phone>
      <email>sylvia.davila1@upr.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvia Perez-Hernandez, M.A., M.P.H., B.S., M.Ed.</last_name>
      <phone>787-764-3083</phone>
      <email>eperez@sanjuanciudadpatria.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Cabotegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?&#xD;
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses?&#xD;
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available?&#xD;
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://submit.mis.s-3.net/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

